BBIO Q1 2023 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+7.8% YoY

Gross Profit

$1M64.3% margin

Operating Income

-$126M-6909.3% margin

Net Income

-$140M-7675.6% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

-$144M

Free Cash Flow

-$144M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$626M

Total Liabilities

$1.8B

Stockholders' Equity

-$1.2B

Cash & Equivalents

$433M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+7.8%
Gross Profit	$1M	$346,000	+239.6%
Operating Income	-$126M	-$174M	+27.4%
Net Income	-$140M	-$196M	+28.6%

Revenue Segments

License and Service

$2M100%